{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:45:02Z","timestamp":1776401102823,"version":"3.51.2"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T00:00:00Z","timestamp":1522627200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s11739-018-1828-8","type":"journal-article","created":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T05:10:32Z","timestamp":1522645832000},"page":"775-790","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Direct-acting antiviral drugs for chronic hepatitis C and risk of major vascular events: a systematic review"],"prefix":"10.1007","volume":"13","author":[{"given":"Eleonora","family":"Tamborini Permunian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Gervaso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Gerdes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Moja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigina","family":"Guasti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Squizzato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,2]]},"reference":[{"issue":"4","key":"1828_CR1","first-page":"234","volume":"2","author":"L Galli","year":"2014","unstructured":"Galli L, Gerdes VE, Guasti L, Squizzato A (2014) Thrombosis associated with viral hepatitis. J Clin Transl Hepatol 2(4):234\u2013239","journal-title":"J Clin Transl Hepatol"},{"issue":"5","key":"1828_CR2","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1055\/s-0032-1315759","volume":"38","author":"A Tufano","year":"2012","unstructured":"Tufano A, Di Capua M, Coppola A, Conca P, Cimino E, Cerbone AM et al (2012) The infectious burden in atherothrombosis. Semin Thromb Hemost 38(5):515\u2013523","journal-title":"Semin Thromb Hemost"},{"key":"1828_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coviro.2014.08.004","volume":"9","author":"J Deval","year":"2014","unstructured":"Deval J, Symons JA, Beigelman L (2014) Inhibition of viral RNA polymerases by nucleoside and nucleotide analogs: therapeutic applications against positive-strand RNA viruses beyond hepatitis C virus. Curr Opin Virol 9:1\u20137","journal-title":"Curr Opin Virol"},{"key":"1828_CR4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.pharmthera.2014.09.002","volume":"145","author":"V Belousova","year":"2015","unstructured":"Belousova V, Abd-Rabou AA, Mousa SA (2015) Recent advances and future directions in the management of hepatitis C infections. Pharmacol Ther 145:92\u2013102","journal-title":"Pharmacol Ther"},{"issue":"349","key":"1828_CR5","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","volume":"2","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, PRISMA-P Group et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2(349):g7647","journal-title":"BMJ"},{"issue":"8","key":"1828_CR6","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2217\/pgs.16.22","volume":"17","author":"A D\u2019Avolio","year":"2016","unstructured":"D\u2019Avolio A, Cusato J, De Nicol\u00f2 A, Allegra S, Di Perri G (2016) Pharmacogenetics of ribavirin-induced anemia in HCV patients. Pharmacogenomics 17(8):925\u2013941","journal-title":"Pharmacogenomics"},{"issue":"4","key":"1828_CR7","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692\u2013694","journal-title":"J Thromb Haemost"},{"issue":"343","key":"1828_CR8","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"18","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, Cochrane Bias Methods Group, Cochrane Statistical Methods Group et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 18(343):d5928","journal-title":"BMJ"},{"key":"#cr-split#-1828_CR9.1","unstructured":"1. Loke YK, Price D, Herxheimer A (2011) Chapter 14: Adverse effects. In: Higgins JPT, Green S"},{"key":"#cr-split#-1828_CR9.2","unstructured":"2. (eds) Cochrane handbook for systematic reviews of interventions??version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.   http:\/\/www.handbook.cochrane.org"},{"issue":"25","key":"1828_CR10","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"IM Jacobson","year":"2011","unstructured":"Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, ADVANCE Study Team et al (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364(25):2405\u20132416","journal-title":"N Engl J Med"},{"issue":"8","key":"1828_CR11","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1056\/NEJMoa1503153","volume":"373","author":"DL Wyles","year":"2015","unstructured":"Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, ALLY-2 Investigators et al (2015) Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 373(8):714\u2013725","journal-title":"N Engl J Med"},{"issue":"27","key":"1828_CR12","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld JJ, Jacobson IM, H\u00e9zode C, Asselah T, Ruane PJ, Gruener N, ASTRAL-1 Investigators et al (2015) Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373(27):2599\u20132607","journal-title":"N Engl J Med"},{"issue":"27","key":"1828_CR13","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","volume":"373","author":"GR Foster","year":"2015","unstructured":"Foster GR, Afdhal N, Roberts SK, Br\u00e4u N, Gane EJ, Pianko S, ASTRAL-2 Investigators, ASTRAL-3 Investigators et al (2015) Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 373(27):2608\u20132617","journal-title":"N Engl J Med"},{"issue":"27","key":"1828_CR14","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","volume":"373","author":"MP Curry","year":"2015","unstructured":"Curry MP, O\u2019Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, ASTRAL-4 Investigators et al (2015) Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373(27):2618\u20132628","journal-title":"N Engl J Med"},{"issue":"1","key":"1828_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1473-3099(14)71002-3","volume":"15","author":"KR Reddy","year":"2015","unstructured":"Reddy KR, Zeuzem S, Zoulim F, Weiland O, Horban A, Stanciu C et al (2015) Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. Lancet Infect Dis 15(1):27\u201335","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"1828_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M15-0785","volume":"163","author":"S Zeuzem","year":"2015","unstructured":"Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y et al (2015) Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 163(1):1\u201313","journal-title":"Ann Intern Med"},{"issue":"2","key":"1828_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jhep.2014.04.004","volume":"61","author":"N Hayashi","year":"2014","unstructured":"Hayashi N, Izumi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H et al (2014) Simeprevir with peginterferon\/ribavirin for treatment-na\u00efve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol 61(2):219\u2013227","journal-title":"J Hepatol"},{"issue":"5","key":"1828_CR18","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00535-014-0949-8","volume":"49","author":"N Izumi","year":"2014","unstructured":"Izumi N, Hayashi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H et al (2014) Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol 49(5):941\u2013953","journal-title":"J Gastroenterol"},{"issue":"1","key":"1828_CR19","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s00535-013-0875-1","volume":"49","author":"N Hayashi","year":"2014","unstructured":"Hayashi N, Seto C, Kato M, Komada Y, Goto S (2014) Once-daily simeprevir (TMC435) with peginterferon\/ribavirin for treatment-na\u00efve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol 49(1):138\u2013147","journal-title":"J Gastroenterol"},{"issue":"20","key":"1828_CR20","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","volume":"368","author":"E Lawitz","year":"2013","unstructured":"Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC et al (2013) Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368(20):1878\u20131887","journal-title":"N Engl J Med"},{"issue":"20","key":"1828_CR21","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","volume":"368","author":"IM Jacobson","year":"2013","unstructured":"Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, POSITRON Study, FUSION Study et al (2013) Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368(20):1867\u20131877","journal-title":"N Engl J Med"},{"issue":"9954","key":"1828_CR22","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S0140-6736(14)61059-X","volume":"384","author":"M Manns","year":"2014","unstructured":"Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, HALLMARK-DUAL Study Team et al (2014) All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 384(9954):1597\u20131605","journal-title":"Lancet"},{"issue":"13","key":"1828_CR23","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","volume":"364","author":"BR Bacon","year":"2011","unstructured":"Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, HCV RESPOND-2 Investigators et al (2011) Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364(13):1207\u20131217","journal-title":"N Engl J Med"},{"issue":"11","key":"1828_CR24","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","volume":"365","author":"KE Sherman","year":"2011","unstructured":"Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, ILLUMINATE Study Team et al (2011) Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 365(11):1014\u20131024","journal-title":"N Engl J Med"},{"issue":"20","key":"1828_CR25","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, ION-1 Investigators et al (2014) Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370(20):1889\u20131898","journal-title":"N Engl J Med"},{"issue":"16","key":"1828_CR26","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, ION-2 Investigators et al (2014) Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370(16):1483\u20131493","journal-title":"N Engl J Med"},{"issue":"20","key":"1828_CR27","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","volume":"370","author":"KV Kowdley","year":"2014","unstructured":"Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, ION-3 Investigators et al (2014) Ledipasvir and sofosbuvir for 8 or 12\u00a0weeks for chronic HCV without cirrhosis. N Engl J Med 370(20):1879\u20131888","journal-title":"N Engl J Med"},{"issue":"6","key":"1828_CR28","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","volume":"15","author":"M Mizokami","year":"2015","unstructured":"Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H et al (2015) Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12\u00a0weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis 15(6):645\u2013653","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"1828_CR29","doi-asserted-by":"publisher","first-page":"744.e3","DOI":"10.1053\/j.gastro.2013.11.047","volume":"146","author":"M Buti","year":"2014","unstructured":"Buti M, Agarwal K, Horsmans Y, Sievert W, Janczewska E, Zeuzem S et al (2014) Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C. Gastroenterology. 146(3):744.e3\u2013753.e3","journal-title":"Gastroenterology."},{"issue":"2","key":"1828_CR30","doi-asserted-by":"publisher","first-page":"359.e1","DOI":"10.1053\/j.gastro.2014.04.045","volume":"147","author":"P Andreone","year":"2014","unstructured":"Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A et al (2014) ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 147(2):359.e1\u2013365.e1","journal-title":"Gastroenterology."},{"issue":"21","key":"1828_CR31","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","volume":"370","author":"P Ferenci","year":"2014","unstructured":"Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, PEARL-III Study, PEARL-IV Study et al (2014) ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 370(21):1983\u20131992","journal-title":"N Engl J Med"},{"issue":"7","key":"1828_CR32","doi-asserted-by":"publisher","first-page":"1669.e3","DOI":"10.1053\/j.gastro.2014.02.051","volume":"146","author":"X Forns","year":"2014","unstructured":"Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P et al (2014) Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology. 146(7):1669.e3\u20131679.e3","journal-title":"Gastroenterology."},{"issue":"9941","key":"1828_CR33","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","volume":"384","author":"IM Jacobson","year":"2014","unstructured":"Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV et al (2014) Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 384(9941):403\u2013413","journal-title":"Lancet"},{"issue":"9941","key":"1828_CR34","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","volume":"384","author":"M Manns","year":"2014","unstructured":"Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y et al (2014) Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 384(9941):414\u2013426","journal-title":"Lancet"},{"issue":"25","key":"1828_CR35","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","volume":"364","author":"S Zeuzem","year":"2011","unstructured":"Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, REALIZE Study Team et al (2011) Telaprevir for retreatment of HCV infection. N Engl J Med 364(25):2417\u20132428","journal-title":"N Engl J Med"},{"issue":"17","key":"1828_CR36","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","volume":"370","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourli\u00e8re M et al (2014) Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370(17):1604\u20131614","journal-title":"N Engl J Med"},{"issue":"13","key":"1828_CR37","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F Poordad","year":"2011","unstructured":"Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, SPRINT-2 Investigators et al (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364(13):1195\u20131206","journal-title":"N Engl J Med"},{"issue":"21","key":"1828_CR38","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","volume":"370","author":"F Poordad","year":"2014","unstructured":"Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K et al (2014) ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 370(21):1973\u20131982","journal-title":"N Engl J Med"},{"issue":"21","key":"1828_CR39","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","volume":"370","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, VALENCE Investigators et al (2014) Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 370(21):1993\u20132001","journal-title":"N Engl J Med"},{"issue":"2","key":"1828_CR40","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/hep.510240201","volume":"24","author":"P Bedossa","year":"1996","unstructured":"Bedossa P, Poynard T (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24(2):289\u2013293","journal-title":"Hepatology"},{"issue":"6","key":"1828_CR41","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.dld.2015.03.006","volume":"47","author":"P Ambrosino","year":"2015","unstructured":"Ambrosino P, Lupoli R, Tarantino P, Di Minno A, Tarantino L, Di Minno MN (2015) Viral hepatitis and anti-phospholipid antibodies positivity: a systematic review and meta-analysis. Dig Liver Dis 47(6):478\u2013487","journal-title":"Dig Liver Dis"},{"issue":"8","key":"1828_CR42","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s12325-014-0138-4","volume":"31","author":"C Enger","year":"2014","unstructured":"Enger C, Forssen UM, Bennett D, Theodore D, Shantakumar S, McAfee A (2014) Thromboembolic events among patients with hepatitis C virus infection and cirrhosis: a matched-cohort study. Adv Ther 31(8):891\u2013903","journal-title":"Adv Ther"},{"issue":"6","key":"1828_CR43","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","volume":"117","author":"RB D\u2019Agostino Sr","year":"2008","unstructured":"D\u2019Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM et al (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117(6):743\u2013753","journal-title":"Circulation"},{"issue":"1","key":"1828_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11239-015-1311-6","volume":"41","author":"JA Heit","year":"2016","unstructured":"Heit JA, Spencer FA, White RH (2016) The epidemiology of venous thromboembolism. J Thromb Thrombolysis 41(1):3\u201314","journal-title":"J Thromb Thrombolysis"},{"issue":"1 Suppl","key":"1828_CR45","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0168-8278(00)80422-5","volume":"32","author":"J Bosch","year":"2000","unstructured":"Bosch J, Garcia-Pagan JC (2000) Complications of cirrhosis. 1. Portal hypertension. J Hepatol 32(1 Suppl):141\u2013156","journal-title":"J Hepatol"},{"issue":"6","key":"1828_CR46","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/0016-5085(89)90526-X","volume":"96","author":"GJ Gores","year":"1989","unstructured":"Gores GJ, Wiesner RH, Dickson ER, Zinsmeister AR, Jorgensen RA, Langworthy A (1989) Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival. Gastroenterology 96(6):1552\u20131559","journal-title":"Gastroenterology"},{"issue":"4","key":"1828_CR47","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.dld.2011.10.016","volume":"44","author":"D Ferro","year":"2012","unstructured":"Ferro D, Angelico F, Caldwell SH, Violi F (2012) Bleeding and thrombosis in cirrhotic patients: what really matters? Dig Liver Dis 44(4):275\u2013279","journal-title":"Dig Liver Dis"},{"issue":"2","key":"1828_CR48","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s11739-014-1168-2","volume":"10","author":"DJ Stuijver","year":"2015","unstructured":"Stuijver DJ, Romualdi E, van Zaane B, Bax L, B\u00fcller HR, Gerdes VE et al (2015) Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis. Intern Emerg Med 10(2):219\u2013246","journal-title":"Intern Emerg Med"},{"key":"1828_CR49","volume-title":"Systematic review on hepatitis B and C prevalence in the EU\/EEA","author":"European Centre for Disease Prevention and Control","year":"2016","unstructured":"European Centre for Disease Prevention and Control (2016) Systematic review on hepatitis B and C prevalence in the EU\/EEA. ECDC, Stockholm"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11739-018-1828-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-018-1828-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-018-1828-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T18:04:44Z","timestamp":1555437884000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11739-018-1828-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,2]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["1828"],"URL":"https:\/\/doi.org\/10.1007\/s11739-018-1828-8","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,2]]},"assertion":[{"value":"28 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human and animal rights"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}